share_log

Armata Pharmaceuticals Enters Secured Credit Agreement With Innoviva Strategic Opportunities, A Wholly-owned Subsidiary Of Innoviva

Moomoo 24/7 ·  Mar 4 16:03

The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses. Proceeds from the $35 million new financing transaction will be used to advance the Company's lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment